Drakenterprises
CardiologyDiabetesFamily MedicineEmergencyOrthopaedicsOtolaryngologyOncologyCross-cutting

Not clinical advice. Clinical Evidence is a current-awareness feed. It is not a clinical decision-support system, not medical advice, and not a substitute for clinical judgment, institutional protocols, or the original sources. Full text, NCCN recommendations, and Cochrane review bodies are not reproduced here.

Home · cross-cutting

JAMAArticle

Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: Research Summary.

JAMA · 09/01/2026

Publication types: Journal Article

PubMed abstract / permitted excerpt

This trial examined whether starting dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, 1 day prior to elective cardiac surgery reduces the risk of acute kidney injury (AKI) in the week following surgery compared with placebo.

Full-text bodies are not stored. Official JAMA Network RSS plus PubMed. No paywall scraping.

Clinical Evidence